Survival analysis using median ISG15 expression level as a cutoff on 162 previously untreated patients with advanced HGSOC showed that patients with high ISG15 expression in the tumor epithelium had a significantly longer median overall survival time (55 months, N = 81, 95% CI:36.9–73.1 months) compared with patients with low expression of ISG15 (29 months, N = 81, 95% CI:23.0–35.0 months), (p < 0.001), (Figure 2D). The gene discussed is ISG15; the disease is neoplasm.